In this podcast, Dr Markman discusses promising findings from a large phase 3 trial comparing subcutaneous tanezumab, a monoclonal antibody with a novel mechanism of action, vs tramadol and placebo among patients with chronic low back pain and history of inadequate response or intolerance to standard-of-care analgesics. This study was featured in the 2020 American Academy of Neurology Science Highlights. For more podcasts like this, visit www.consultant360.com/neurology.